Effects of Eicosapentaenoic Acid vs Eicosapentaenoic/Docosahexaenoic Acids on Cardiovascular Mortality
EPA lowered incident CVD-attributable mortality in RCTs investigating its use for primary or secondary CVD prevention. Relative to EPA, benefits reported with EPA/DHA were attenuated. Although more work is needed to understand these differences, EPA should preferentially be used in cardiovascular conditions for which it is indicated.
Authors
- Deepak L. Bhatt (ORCID: https://orcid.org/0000-0002-1278-6245)
- John P. Sheppard (ORCID: https://orcid.org/0000-0002-8040-8481)
- Thomas Drago (ORCID: https://orcid.org/0000-0002-6380-3930)
- Jaspreet Bhogal
- Leonard Palatnic
- John Nelson (ORCID: https://orcid.org/0000-0003-2455-0296)
- Matthew Jay Budoff (ORCID: https://orcid.org/0000-0002-9616-1946)
- Suvasini Lakshmanan (ORCID: https://orcid.org/0009-0005-2147-4576)
- Sion Roy
Institutions
- Cedars-Sinai Medical Center (US)
- UCLA Medical Center (US)
- Mount Sinai Hospital (US)
- Cedars-Sinai Smidt Heart Institute (US)
- Harbor–UCLA Medical Center (US)
- University at Buffalo, State University of New York (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102149
- Citations
- 2
- Primary Topic
- Fatty Acid Research and Health
- Type
- article
- Field-Weighted Citation Impact
- 2.24